Development of a population pharmacokinetics model and an R-Shiny simulation platform for moxifloxacin pharmacokinetics in non-human primates
Abstract
Assessment of potential liability of prolonged cardiac repolarization for a new drug is critical in drug research and development. Moxifloxacin is used as a positive control in well controlled in-vivo experiments to evaluate cardiac safety in preclinical species. A limited number of pharmacokinetic (PK) samples are collected in these experiments due to practical challenges, thus limiting the full utilization of extensive QT data collected every minute. Therefore, the objective of this work was to develop a population pharmacokinetics model of moxifloxacin in non-human primates (NHP) to enable concentration-QTc evaluation of all available telemetered ECG data. A user-friendly R Shiny simulation platform was developed which allows researchers to predict full PK profiles using limited PK data. A cardiovascular telemetry study was conducted in NHPs (n = 48, 50% females) with pharmacokinetic samples from 47 NHPs collected on 4 separate periods after an 80 mg/kg oral dose of moxifloxacin. Periods 1 (at 6 and 24 h on Day 3) and 2 (at 6 and 24 h on Day 10) had sparse PK samples and Periods 3 and 4 (Days 15 and 17) collected serial PK samples for 48 h post dose. Population PK modeling was performed using R package nlmixr2, R package rxode2 (Version 2.1.3) was used for simulations, and R Version 4.3.0 was used. The simulation platform was created using Shiny for R. Moxifloxacin PK in NHPs (body weight range: 2.83–6.67 kg) was best described with a one compartment, first-order…
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.